454 Life Sciences and Baylor College of Medicine complete sequencing of DNA pioneer

Jun 01, 2007

[B]The genome of James Watson is the first to be sequenced for less than $1M[/B]
454 Life Sciences Corporation, in collaboration with scientists at the Human Genome Sequencing Center, Baylor College of Medicine, announced today in Houston, Texas, the completion of a project to sequence the genome of James D. Watson, Ph.D., co-discoverer of the double-helix structure of DNA. The mapping of Dr. Watson’s genome was completed using the Genome Sequencer FLX™ system and marks the first individual genome to be sequenced for less than $1 million.

“When we began the Human Genome Project, we anticipated it would take 15 years to sequence the 3 billion base pairs and identify all the genes,” said Richard Gibbs, Ph.D. , director, Human Genome Sequencing Center, Baylor College of Medicine. “We completed it in 13 years in 2003 – coinciding with the 50th anniversary of the publication of the work of Watson and Dr. Francis Crick that described the double helix. Today, we give James Watson a DVD containing his personal genome – a project completed in only two months. It demonstrates how far sequencing technology has come in a short time.”

Christopher McLeod, president and CEO of 454 Life Sciences, added: “The sequencing of Dr. Watson’s genome validates the approach taken by 454 Life Sciences in developing a technology to make the sequencing of individual human genomes quick and affordable. As we take another step on the path toward the X-Prize and reducing the cost of human genome sequencing to $10,000, we hope to enable a new era of medicine that is tailored to a patient's unique genetic profile.”

Michael Egholm, Ph.D., vice president of research and development of 454 Life Sciences, said: “The sequencing of Dr. Watson’s genome has been done on production Genome Sequencer FLX™ systems, where we could take advantage of the instrument’s high quality data and long read lengths. Using the unbiased 454 Sequencing™ technology, we obtained a near complete picture of Dr. Watson's genome and were able to identify missing pieces of the public reference genome generated by the Human Genome Project. By making his genome publicly available, Dr. Watson will provide a tremendous resource to researchers and future generations.”

Dr. Watson will receive a DVD with his genomic sequence. He will decide which of his data will be published.

“When I conceived the 454 Sequencing™ technology, I envisioned making routine individual genome sequencing a reality to help with personal medical care,” said Jonathan Rothberg, founder and former chairman of 454 Life Sciences. “Since Dr. Watson is the co-discoverer of DNA’s structure and 1962 Nobel Laureate, it is only appropriate to work with him on this ambitious genome sequencing project. This project will pave the way for exploring life at the ultimate level by uncovering what makes each individual unique.”


Source: Russo Partners, LLC

Explore further: Researchers develop model for better testing, targeting of malignant peripheral nerve sheath tumors

add to favorites email to friend print save as pdf

Related Stories

New 'bench top' machines open up DNA sequencing

Apr 27, 2012

(Phys.org) -- Research carried out by scientists at the University of Birmingham have found that new ‘bench-top’ machines for sequencing DNA are capable of accurately identifying over 95% of a genome, signalling ...

Tasmanian devil's genome sequenced

Jun 27, 2011

A revolutionary species-preservation approach based on whole-genome analyses of two Tasmanian devils -- one that had died of a contagious cancer known as Devil Facial Tumor Disease (DFTD) and one healthy animal ...

Recommended for you

User comments : 0

More news stories

If you can remember it, you can remember it wrong

(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...

B vitamins could delay dementia

(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...

Reducing caloric intake delays nerve cell loss

Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...

New sleeping pill poised to hit US markets

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Changing cancer's environment to halt its spread

By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces ...

New method for producing clean hydrogen

Duke University engineers have developed a novel method for producing clean hydrogen, which could prove essential to weaning society off of fossil fuels and their environmental implications.